首頁 > 市場調查報告書 > 製藥

生物製劑

市場調查報告書

商品編碼

1909112

生物製劑CDMO市場規模、佔有率和成長分析（按服務類型、生產平台、治療模式、最終用戶和地區分類）－2026-2033年產業預測

Biologics CDMO Market Size, Share, and Growth Analysis, By Service Type, By Production Platform, By Modality Type, By End-User, By Region - Industry Forecast 2026-2033

出版日期: 2026年01月02日 | 出版商:

SkyQuest | 英文 181 Pages | 商品交期: 3-5個工作天內

價格

簡介目錄

全球生物製劑 CDMO 市場規模預計在 2024 年達到 246.2 億美元，從 2025 年的 284.6 億美元成長到 2033 年的 907.7 億美元，在預測期（2026-2033 年）內複合年成長率為 15.6%。

由於包括單株抗體、疫苗和先進治療方法在內的生物製劑需求不斷成長，以及生物製藥公司外包趨勢日益明顯，全球生物製劑CDMO市場需求持續強勁。 CDMO的專業知識和專業能力，以及臨床研發管線中生物製劑數量的不斷增加，加速了生物製劑的市場進入。然而，該市場也面臨許多挑戰，包括高額資本支出、複雜的法規環境以及部分地區熟練勞動力短缺。智慧財產權問題和整合風險也構成額外的障礙。儘管存在這些挑戰，但戰略合作、一次性生物反應器等技術進步以及生物製造設施的持續發展將確保該行業的持續成長，長期前景仍然樂觀。

全球生技藥品CDMO市場促進因素

慢性病發病率的上升和生物製藥需求的不斷成長，顯著推動了大規模生物製藥生產的需求。隨著生物相似藥研發的加速推進以及生物製藥公司尋求更高的營運效率，製藥和生物技術產業越來越依賴受託製造廠商（CDMO）。這些合作關係使企業能夠充分利用CDMO的專業知識，最佳化資源配置，並加速產品上市速度。這一趨勢反映了企業策略的轉變，即透過與CDMO合作來提高生產效率，並在競爭激烈的環境中滿足生物製藥行業不斷變化的需求。

全球生技藥品CDMO市場面臨的限制因素

全球生物製藥CDMO市場面臨許多限制因素，主要源自於生產營運所需的大量資本投入。建造先進的基礎設施、無塵室和專用設施會帶來沉重的財務負擔。生物製藥加工工藝複雜，涉及細胞培養和純化等諸多環節，進一步加劇了市場格局的複雜性，並要求具備熟練的勞動力、嚴格的管控措施以及深厚的生產技術專長。因此，資金障礙可能阻礙新的合約研發生產機構（CDMO）進入市場，而現有企業若缺乏充足的資金和資源，也難以有效拓展業務，可能阻礙整個產業的成長。

全球生技藥品CDMO市場趨勢

全球生物製藥CDMO市場正經歷著向一次性（可拋棄式）技術的廣泛應用的重大轉變。這些創新系統透過提高柔軟性和最大限度地降低污染風險，提升了營運效率並簡化了生產流程。快速換線提高了生產力，並有助於實施可擴展的生產模式，這對於多產品生產設施以及快速發展的個人化醫療和臨床治療領域尤其有利。隨著生物製藥生產對敏捷性和客製化的需求不斷成長，一次性技術有望在塑造CDMO產業的未來中發揮關鍵作用。

北美洲
- 美國
- 加拿大
歐洲
- 德國
- 西班牙
- 法國
- 英國
- 義大利
- 其他歐洲地區
亞太地區
- 中國
- 印度
- 日本
- 韓國
- 亞太其他地區
拉丁美洲
- 巴西
- 其他拉丁美洲地區
中東和非洲
- 海灣合作理事會國家
- 南非
- 其他中東和非洲地區

競爭資訊

前五大公司對比
主要企業的市場定位（2025 年）
主要市場參與者所採取的策略
近期市場趨勢
公司市佔率分析（2025 年）
主要企業公司簡介
- 公司詳情
- 產品系列分析
- 依業務板塊進行公司股票分析
- 2023-2025年營收年比比較

主要企業簡介

Lonza Group Ltd.
Samsung Biologics
Catalent, Inc.
WuXi Biologics Cayman Inc.
Thermo Fisher Scientific Inc.
AGC Biologics
Boehringer Ingelheim BioXcellence
3P Biopharmaceuticals
FUJIFILM Diosynth Biotechnologies
Binex Co. Ltd.
Patheon（part of Thermo Fisher）
Recipharm AB
BioVectra Inc.
Janssen Biotechnology Services（Johnson & Johnson）
AbbVie Contract Manufacturing（AbbVie）
Charles River Laboratories（Biologics CDMO division）
Catalent Biologics（subsidiary of Catalent）
Philips-Morris Scientific Services（CDMO arm）
Celltrion Technologies Corporation
KanaBio Sciences Inc.

結論與建議

簡介目錄

Product Code: SQMIG35H2392

Global Biologics CDMO Market size was valued at USD 24.62 Billion in 2024 and is poised to grow from USD 28.46 Billion in 2025 to USD 90.77 Billion by 2033, growing at a CAGR of 15.6% during the forecast period (2026-2033).

The global biologics CDMO market is experiencing heightened demand driven by the increasing requirement for biologics such as monoclonal antibodies, vaccines, and advanced therapies, alongside a growing trend in biopharma companies to outsource operations. The expertise and specialized capabilities of CDMOs facilitate faster market entry for biologics, bolstered by an expanding number of biologics in clinical pipelines. However, this market faces challenges including high capital expenditures, complex regulatory environments, and limited skilled labor in some regions. Intellectual property concerns and integration risks also pose additional barriers. Despite these obstacles, the long-term outlook remains positive due to strategic partnerships, advancements in technology like single-use bioreactors, and the ongoing development of biomanufacturing facilities, ensuring sustained growth in the sector.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Biologics CDMO market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Biologics CDMO Market Segments Analysis

Global Biologics CDMO Market is segmented by Service Type, Production Platform, Modality Type, End-User and region. Based on Service Type, the market is segmented into Process Development & Cell Line Development, Drug Substance Manufacturing, Drug Product / Fill-Finish & Packaging, Analytical / Testing / QC Services and End-to-End / Integrated CDMO Services. Based on Production Platform, the market is segmented into Mammalian Systems, Microbial Systems and Other Platforms. Based on Modality Type, the market is segmented into Monoclonal Antibodies (mAbs), Recombinant Proteins, Biosimilars, Cell & Gene Therapies / Viral Vectors and Other Biologics. Based on End-User, the market is segmented into Large Pharmaceutical Companies, Biotechnology / Small & Mid-Sized Biotechs, Academic & Research Institutes and Government / Public Sector Contracts. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & Africa.

Driver of the Global Biologics CDMO Market

The rise in chronic diseases and the growing demand for biologic products have significantly boosted the necessity for large-scale biologics manufacturing. As the development of biosimilars accelerates and biologics companies seek greater operational efficiencies, the pharmaceutical and biotechnology sectors are increasingly relying on contract development and manufacturing organizations (CDMOs). These partnerships enable companies to leverage specialized expertise, optimize resource allocation, and reduce time to market. This trend reflects a strategic shift towards collaboration with CDMOs to enhance productivity and meet the evolving needs of the biopharmaceutical landscape in an increasingly competitive environment.

Restraints in the Global Biologics CDMO Market

The Global Biologics CDMO market faces significant restraints primarily due to the considerable capital investment required for manufacturing operations. Establishing advanced infrastructure, cleanrooms, and specialized equipment demands a hefty financial commitment. The complexity of biologics processes, which encompasses intricate procedures like cell culture and purification, further complicates the landscape, necessitating skilled labor, rigorous controls, and deep expertise in manufacturing methodologies. As a result, financial barriers can inhibit new Contract Development and Manufacturing Organizations (CDMOs) from entering the market, while existing players may struggle to scale their operations effectively without sufficient financial backing and resources, hindering overall growth within the industry.

Market Trends of the Global Biologics CDMO Market

The global biologics Contract Development and Manufacturing Organization (CDMO) market is witnessing a significant shift towards the widespread adoption of single-use technologies. These innovative systems are enhancing operational efficiency by increasing flexibility and minimizing contamination risks, thereby streamlining production processes. The ability to conduct faster changeovers contributes to improved productivity, allowing companies to implement scalable production models that are particularly beneficial for multi-product facilities and the burgeoning field of personalized or clinical therapeutics. As demand for agility and customization in biologics manufacturing continues to rise, single-use technologies are poised to play a pivotal role in shaping the future of the CDMO landscape.

Introduction

Objectives of the Study
Scope of the Report
Definitions

Research Methodology

Information Procurement
Secondary & Primary Data Methods
Market Size Estimation
Market Assumptions & Limitations

Executive Summary

Global Market Outlook
Supply & Demand Trend Analysis
Segmental Opportunity Analysis

Market Dynamics & Outlook

Market Overview
Market Size
Market Dynamics
- Drivers & Opportunities
- Restraints & Challenges
Porters Analysis
- Competitive rivalry
- Threat of substitute
- Bargaining power of buyers
- Threat of new entrants
- Bargaining power of suppliers

Key Market Insights

Key Success Factors
Degree of Competition
Top Investment Pockets
Market Ecosystem
Market Attractiveness Index, 2025
PESTEL Analysis
Macro-Economic Indicators
Value Chain Analysis
Pricing Analysis
Technology Assessment
Regulatory Landscape

Global Biologics CDMO Market Size by Service Type & CAGR (2026-2033)

Market Overview
Process Development & Cell Line Development
Drug Substance Manufacturing
Drug Product / Fill-Finish & Packaging
Analytical / Testing / QC Services
End-to-End / Integrated CDMO Services

Global Biologics CDMO Market Size by Production Platform & CAGR (2026-2033)

Market Overview
Mammalian Systems
Microbial Systems
Other Platforms

Global Biologics CDMO Market Size by Modality Type & CAGR (2026-2033)

Market Overview
Monoclonal Antibodies (mAbs)
Recombinant Proteins
Biosimilars
Cell & Gene Therapies / Viral Vectors
Other Biologics

Global Biologics CDMO Market Size by End-User & CAGR (2026-2033)

Market Overview
Large Pharmaceutical Companies
Biotechnology / Small & Mid-Sized Biotechs
Academic & Research Institutes
Government / Public Sector Contracts

Global Biologics CDMO Market Size & CAGR (2026-2033)

North America (Service Type, Production Platform, Modality Type, End-User)
- US
- Canada
Europe (Service Type, Production Platform, Modality Type, End-User)
- Germany
- Spain
- France
- UK
- Italy
- Rest of Europe
Asia Pacific (Service Type, Production Platform, Modality Type, End-User)
- China
- India
- Japan
- South Korea
- Rest of Asia-Pacific
Latin America (Service Type, Production Platform, Modality Type, End-User)
- Brazil
- Rest of Latin America
Middle East & Africa (Service Type, Production Platform, Modality Type, End-User)
- GCC Countries
- South Africa
- Rest of Middle East & Africa

Competitive Intelligence

Top 5 Player Comparison
Market Positioning of Key Players, 2025
Strategies Adopted by Key Market Players
Recent Developments in the Market
Company Market Share Analysis, 2025
Company Profiles of All Key Players
- Company Details
- Product Portfolio Analysis
- Company's Segmental Share Analysis
- Revenue Y-O-Y Comparison (2023-2025)

Key Company Profiles

Lonza Group Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Samsung Biologics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Catalent, Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
WuXi Biologics Cayman Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Thermo Fisher Scientific Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AGC Biologics
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Boehringer Ingelheim BioXcellence
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
3P Biopharmaceuticals
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
FUJIFILM Diosynth Biotechnologies
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Binex Co. Ltd.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Patheon (part of Thermo Fisher)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Recipharm AB
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
BioVectra Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Janssen Biotechnology Services (Johnson & Johnson)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
AbbVie Contract Manufacturing (AbbVie)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Charles River Laboratories (Biologics CDMO division)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Catalent Biologics (subsidiary of Catalent)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Philips-Morris Scientific Services (CDMO arm)
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
Celltrion Technologies Corporation
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments
KanaBio Sciences Inc.
- Company Overview
- Business Segment Overview
- Financial Updates
- Key Developments